We are live on
!
Find out more
Pacer Advisors Portfolio holdings
AUM
$35.6B
1-Year Est. Return
18.19%
This Fund
S&P 500
This Quarter
Est. Return
+6.36%
1 Year Est. Return
+18.19%
3 Year Est. Return
+46.13%
5 Year Est. Return
+70.99%
10 Year Est. Return
+394.12%
AUM
$5.75B
AUM Growth
+$430M
(+8.1%)
Cap. Flow
-$1.1B
Cap. Flow
% of AUM
-19.08%
Top 10 Holdings %
Top 10 Hldgs %
27.15%
Holding
1,587
New
76
Increased
378
Reduced
937
Closed
183
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Newmont
NEM
|
+$6.27M |
| 2 |
TJX Companies
TJX
|
+$5.89M |
| 3 |
General Mills
GIS
|
+$5.87M |
| 4 |
HP
HPQ
|
+$5.84M |
| 5 |
Ford
F
|
+$5.38M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$16.7M |
| 2 |
Amazon
AMZN
|
+$14.9M |
| 3 |
Iron Mountain
IRM
|
+$14.6M |
| 4 |
Microsoft
MSFT
|
+$12.9M |
| 5 |
GDS Holdings
GDS
|
+$9.75M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 17.47% |
| 2 | Technology | 14.6% |
| 3 | Consumer Discretionary | 9.29% |
| 4 | Healthcare | 7.36% |
| 5 | Communication Services | 6.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1201
Alkermes
ALKS
$8.42B
| $75K | ﹤0.01% |
4,014
-2,230
| -36% | -$45.6K |
|
1202
Heron Therapeutics
HRTX
$92M
| $75K | ﹤0.01% |
4,604
-196
| -4% | -$3.49K |
|
1203
Seres Therapeutics
MCRB
$46.5M
| $75K | ﹤0.01% |
182
-90
| -33% | -$41.4K |
|
1204
Opko Health
OPK
$1.25B
| $75K | ﹤0.01% |
17,566
-12,172
| -41% | -$58.1K |
|
1205
Revolution Medicines
RVMD
$39.1B
| $75K | ﹤0.01% |
1,630
-642
| -28% | -$28.8K |
|
1206
TG Therapeutics
TGTX
$8.4B
| $75K | ﹤0.01% |
1,562
-1,568
| -50% | -$75.3K |
|
|
VBIV
1207
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $75K | ﹤0.01% |
805
-537
| -40% | -$54.4K |
|
1208
Acadia Pharmaceuticals
ACAD
$4.45B
| $74K | ﹤0.01% |
2,882
+298
| +12% | +$13.1K |
|
1209
ALX Oncology
ALXO
$268M
| $74K | ﹤0.01% |
1,010
+564
| +126% | +$44.4K |
|
1210
Immunovant
IMVT
$7.99B
| $74K | ﹤0.01% |
4,594
+2,184
| +91% | +$57.6K |
|
1211
Kura Oncology
KURA
$826M
| $74K | ﹤0.01% |
2,618
-558
| -18% | -$17.7K |
|
|
SAGE
1212
DELISTED
Sage Therapeutics
SAGE
| $74K | ﹤0.01% |
991
-962
| -49% | -$78.9K |
|
1213
Akebia Therapeutics
AKBA
$341M
| $73K | ﹤0.01% |
21,604
-20,146
| -48% | -$72.6K |
|
|
ALLK
1214
DELISTED
Allakos
ALLK
| $73K | ﹤0.01% |
633
-260
| -29% | -$32.8K |
|
|
BLUE
1215
DELISTED
bluebird bio
BLUE
| $73K | ﹤0.01% |
186
-54
| -23% | -$26.6K |
|
1216
Sutro Biopharma
STRO
$393M
| $73K | ﹤0.01% |
+322
| New | +$76.4K |
|
|
SWTX
1217
DELISTED
SpringWorks Therapeutics
SWTX
| $73K | ﹤0.01% |
988
-322
| -25% | -$25.2K |
|
1218
Allogene Therapeutics
ALLO
$573M
| $72K | ﹤0.01% |
2,028
-2,802
| -58% | -$94.5K |
|
|
APLS
1219
DELISTED
Apellis Pharmaceuticals
APLS
| $72K | ﹤0.01% |
1,669
-986
| -37% | -$46.7K |
|
1220
BioXcel Therapeutics
BTAI
$26.1M
| $72K | ﹤0.01% |
104
-88
| -46% | -$70.8K |
|
|
ESPR
1221
DELISTED
Esperion Therapeutics
ESPR
| $72K | ﹤0.01% |
2,572
-1,664
| -39% | -$49.1K |
|
|
FOLD
1222
DELISTED
Amicus Therapeutics
FOLD
| $72K | ﹤0.01% |
7,238
+1,252
| +21% | +$19.4K |
|
|
IMGN
1223
DELISTED
Immunogen Inc
IMGN
| $72K | ﹤0.01% |
8,846
-2,440
| -22% | -$19.9K |
|
|
GBT
1224
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $72K | ﹤0.01% |
1,772
-1,478
| -45% | -$67.9K |
|
|
DRNA
1225
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $72K | ﹤0.01% |
2,800
-384
| -12% | -$9.81K |
|
Similar funds
SAM
Pacer Advisors's Q1 2021 Portfolio in Review
As of Q1 2021, Pacer Advisors held 1,587 positions worth $5.75B, up 8.1% from $5.32B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Pacer Advisors withdrew a net $1.1B in Q1 2021, closing 183 positions and reducing 937 holdings. Its most notable exit was Rithm Capital, an estimated $4.39M position sold in full.
By sector, the portfolio is most concentrated in Real Estate at 17% of assets, down from 18% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Pacer Advisors opened a new position in Aerojet Rocketdyne Holdings worth $3.39M.
- Pacer Advisors's largest Q1 2021 buy was Aerojet Rocketdyne Holdings: 72,150 shares worth $3.39M.
- Pacer Advisors added most to Newmont in Q1 2021, an estimated $6.27M increase.
- Pacer Advisors's biggest Q1 2021 reduction was Apple, cutting an estimated $16.7M.
- Pacer Advisors fully exited Rithm Capital in Q1 2021, selling an estimated $4.39M.
- Pacer Advisors's ten largest holdings make up 27% of its $5.75B portfolio in Q1 2021.
- Pacer Advisors opened 76 new positions and closed 183 in Q1 2021.
- Pacer Advisors's portfolio value rose 8.1% quarter-over-quarter to $5.75B.
Based on Pacer Advisors's 13F filing for Q1 2021, filed 5 Apr 2021.